A Phase IV Enhanced Safety Surveillance Study of ACAM2000 in Military Personnel.
Phase of Trial: Phase IV
Latest Information Update: 01 Feb 2018
At a glance
- Drugs ACAM 2000 (Primary)
- Indications Smallpox
- Focus Adverse reactions
- Sponsors Emergent BioSolutions; Sanofi; sanofi pasteur
- 26 Jan 2018 Status changed from active, no longer recruiting to completed.
- 16 May 2017 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017.
- 16 May 2017 Planned primary completion date changed from 1 Apr 2016 to 1 Dec 2017.